cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Eligibility

Selection Criteria:

* Patient included in NeckTAR study
* Written informed consent signed for NeckTAR-IN study
* Affiliation to the French social security system

Conditions2

Interventions1

Related trials

• Analysis of Circulating Tumor Markers in Blood — Institut du Cancer de Montpellier - Val d'Aurelle
• B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer. — Poitiers University Hospital
• Biobank for Inflammatory Chronic Diseases and Osteoporosis — University Hospital, Toulouse
• Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer. — Hospices Civils de Lyon
• Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis — Assistance Publique - Hôpitaux de Paris
• Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer — Hospices Civils de Lyon
• Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases — University Hospital, Toulouse
• Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases — University Hospital, Toulouse

Browse More Trials